3:59 PM
 | 
Dec 04, 2018
 |  BC Extra  |  Preclinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first compounds Yumanity has disclosed from its yeast discovery platform. The company plans to enter the clinic with lead SCD1 inhibitor, YTX-7739, in 4Q19 to treat PD.

In a paper published in Cell Reports Tuesday, the team showed that the SCD1 inhibitors decreased α-synuclein toxicity and...

Read the full 383 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >